期刊
CANCER RESEARCH
卷 68, 期 20, 页码 8626-8634出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-08-1218
关键词
-
类别
资金
- Guido Berlucchi Foundation,
- Center for the Study, Prevention and Therapy of Hepatic Diseases
- Spedali Civili Brescia
- Foridazione FRCCS Istituto Neurologico [LR6]
Hepatocellular carcinoma (HCC) is one of most malignant and aggressive human tumors. Transforming growth factor-01 (TGF-beta 1) and its coreceptor CD105 have been shown to contribute to HCC malignant progression. TGF-beta 1 and CD105 have also been implicated in angiogenesis, but their role in the vascularization of HCC has not been investigated. To fill this gap, we studied the effect of TGF-beta 1 and CD105 on HCC-derived endothelium. By using immunomagnetic beads, we isolated and cultured endothelial cells (ECs) from HCC (HCC-EC) and adjacent nonneoplastic tissue (nNL-ECs) obtained from 24 liver biopsies. HCC and nNL biopsies were also analyzed by immunohistochemistry for the expression of CD105, TGF-beta 1, Ve-cadherin (Ve-cad), CD44, beta-catenin, and E-cadherin. Compared with nNL-ECs, HCC-ECs had higher expression of CD105, enhanced spontaneous motility, and greater capacity to migrate in response to TGF-beta 1 (5 ng/mL), particularly in the presence of a fibronectin matrix. The chemotactic effect of TGF-beta 1 was blocked by anti-CD105 antibodies and correlated with the grade of HCC malignancy. Histologic examination of HCC biopsies showed that HCCs with the worse malignant features had the highest expression of TGF- I, CD105, and angiogenic markers (Ve-cad and CD44). Because CD105 was highly expressed in microvessels at the tumor periphery and TGF-beta 1 staining was only found in neoplastic hepatocytes, we conclude that HCC-derived TGF-beta 1 may act as a chemoattractant for CD105-expressing ECs and as a promoter of tumor angiogenesis. Thus, drugs that selectively target the TGF beta 1/CD105 axis may interfere with HCC-related angiogenesis and HCC progression. [Cancer Res 2008;68(20):8626-34]
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据